Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.59 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.59 |
| ▸ | SELL | P14151 | 3/20 | 0.44 |
| ▸ | SELP | P16109 | 3/20 | 0.44 |
| ▸ | SELE | P16581 | 3/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | LDHA | P00338 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | GJB2 | P29033 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | TLR4 | O00206 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sucrose SCHEMBL949885 | 1.00 | CDK1 (0.59) | CDK1CCNB1SELLSELPSELE | |
| Sucrose SCHEMBL285512 | 1.00 | CDK1 (0.59) | CDK1CCNB1SELLSELPSELE | |
| Sucrose SCHEMBL1067854 | 1.00 | CDK1 (0.59) | CDK1CCNB1SELLSELPSELE | |
| Sucrose SCHEMBL5030245 | 1.00 | CDK1 (0.59) | CDK1CCNB1SELLSELPSELE | |
| Sucrose SCHEMBL1874820 | 1.00 | CDK1 (0.59) | CDK1CCNB1SELLSELPSELE | |
| Sucrose SCHEMBL21121139 | 1.00 | CDK1 (0.59) | CDK1CCNB1SELLSELPSELE | |
| Sucrose SCHEMBL16859920 | 1.00 | CDK1 (0.59) | CDK1CCNB1SELLSELPSELE | |
| Sucrose SCHEMBL285432 | 1.00 | CDK1 (0.59) | CDK1CCNB1SELLSELPSELE | |
| Sucrose SCHEMBL10694059 | 1.00 | CDK1 (0.59) | CDK1CCNB1SELLSELPSELE | |
| Sucrose SCHEMBL3947585 | 1.00 | CDK1 (0.59) | CDK1CCNB1SELLSELPSELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4694687-A1 | A METHOD FOR PRESERVING OR ENHANCING YIELD OF A FIELD-CULTIVATED CROP EXPOSED TO AT LEAST ONE ABIOTIC STRESS | Elicit Plant (FR) | 2026-02-18 | — | — | EP | disclosed |
| US-12508218-B2 | Coating compositions | COTY INC. (US) | 2025-12-30 | — | — | US | disclosed |
| EP-3103523-B1 | ABSORBENT ARTICLE COMPRISING FRAGRANCE COMPOSITION | PROCTER & GAMBLE (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250152487-A1 | FRAGRANCE COMPOSITIONS AND USES THEREOF | COTY INC. | 2025-05-15 | — | — | US | disclosed |
| US-20250154167-A1 | METHOD OF TREATMENT OF SYMPTOMS OF MENOPAUSE | KaNDy Therapeutics Limited (GB) | 2025-05-15 | — | — | US | disclosed |
| CN-119950513-A | Novel pharmaceutical formulations containing dual NK-1/NK-3 receptor antagonists | KaNDy治疗有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20250127707-A1 | FRAGRANCE FORMULATION | COTY INC. | 2025-04-24 | — | — | US | disclosed |
| US-20250127694-A1 | FRAGRANCE COMPOSITIONS AND USES THEREOF | COTY INC. | 2025-04-24 | — | — | US | disclosed |
| US-12264164-B2 | Method of treatment of symptoms of menopause | KaNDy Therapeutics Limited (GB) | 2025-04-01 | — | — | US | disclosed |
| WO-2025061637-A1 | METHOD FOR MATCHING THE PHYTOSTEROL CONTENT OF AN AGRICULTURAL COMPOSITION TO THAT OF TARGET PLANT SPECIES FOR IMPROVING BIOSTIMULATION | ELICIT PLANT (FR) | 2025-03-27 | — | — | WO | disclosed |
| US-9999578-B2 | Translucent and syrupy cosmetic composition | CHANEL PARFUMS BEAUTE (FR) | 2018-06-19 | — | — | US | disclosed |
| EP-3141239-A1 | FRAGRANCE COMPOSITIONS AND USES THEREOF | The Procter and Gamble Company (US) | 2017-03-15 | — | — | EP | disclosed |
| US-20160362629-A1 | Fragrance Compositions and Uses Thereof | THE PROCTER & GAMBLE COMPANY | 2016-12-15 | — | — | US | disclosed |
| US-20160362630-A1 | Fragrance Compositions and Uses Thereof | THE PROCTER & GAMBLE COMPANY | 2016-12-15 | — | — | US | disclosed |
| EP-3103431-A1 | FRAGRANCE COMPOSITIONS AND USES THEREOF | The Procter and Gamble Company (US) | 2016-12-14 | — | — | EP | disclosed |
| EP-3103523-A1 | ABSORBENT ARTICLE COMPRISING FRAGRANCE COMPOSITION | The Procter and Gamble Company (US) | 2016-12-14 | — | — | EP | disclosed |
| CN-106137787-A | Emulsification composition of reduced coenzyme Q 10 and preparation method thereof | 伊比西(北京)植物药物技术有限公司 | 2016-11-23 | — | — | CN | disclosed |
| EP-2720671-B1 | TRANSLUCENT AND SYRUPY COSMETIC COMPOSITION | CHANEL PARFUMS BEAUTÉ (FR) | 2016-05-25 | — | — | EP | disclosed |
| US-20140120043-A1 | TRANSLUCENT AND SYRUPY COSMETIC COMPOSITION | CHANEL PARFUMS BEAUTE (FR) | 2014-05-01 | — | — | US | disclosed |
| WO-2009022044-A1 | SOLUBLE CAROTENOID MOLECULAR COMPLEX OR AGGREGATE, METHOD FOR OBTAINING SAME AND USE THEREOF | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127694-A1 | FRAGRANCE COMPOSITIONS AND USES THEREOF | TRPA1, TRPV1, NAA40 | CDK1 3873/4885CCNB1 4448/4885SELL 4372/4885 |
| US-20160362629-A1 | Fragrance Compositions and Uses Thereof | CUTA, ELOVL5, TRPC5 | CDK1 3809/4885CCNB1 4307/4885SELL 3448/4885 |
| US-20250127707-A1 | FRAGRANCE FORMULATION | PUF60, POLM, ADH5 | CDK1 3597/4885CCNB1 2697/4885SELL 4425/4885 |
| US-20160362630-A1 | Fragrance Compositions and Uses Thereof | CUTA, DPM1, PLIN5 | CDK1 3377/4885CCNB1 3796/4885SELL 4267/4885 |
| US-12508218-B2 | Coating compositions | TAS2R40, TAS2R20, TAS2R10 | CDK1 3208/4885CCNB1 4129/4885SELL 648/4885 |
| US-12264164-B2 | Method of treatment of symptoms of menopause | CYP19A1, MTNR1B, SHBG | CDK1 1589/4885CCNB1 1392/4885SELL 4251/4885 |
| US-20250152487-A1 | FRAGRANCE COMPOSITIONS AND USES THEREOF | FHIT, ALG3, FEM1B | CDK1 4776/4885CCNB1 4327/4885SELL 3872/4885 |
| US-20250154167-A1 | METHOD OF TREATMENT OF SYMPTOMS OF MENOPAUSE | CYP19A1, MTNR1B, SHBG | CDK1 1589/4885CCNB1 1392/4885SELL 4251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.